Janumet is an antidiabetic medicine that contains two different active ingredients: metformin HCl and sitagliptin. Sitagliptin is a type of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, while metformin HCl is an antihyperglycemic agent pharmacologically (and chemically) unrelated to any other types of diabetes drugs. Sitagliptin is able to slow the inactivation of incretin, thereby prolonging its actions. On the other hand, metformin helps increase peripheral uptake (and utilization) of glucose, thereby improving insulin sensitivity. Janumet 50mg/500mg comes in the form of film-coated tablets. Formulations in higher doses are also available. This diabetes drug is only available by prescription. Janumet is a product of the US-based Merck.
Janumet is indicated for the treatment of type II diabetes. It helps adult patients with elevated blood sugar levels to enhance their glycemic control. Be aware that Janumet is not effective in treating diabetic ketoacidosis or type I diabetes mellitus. Use Janumet cautiously if you previously have had pancreatitis. For optimal treatment outcomes, this drug should be used in combination with diet or exercise. While using Janumet, patients should closely follow lifestyle recommendations made by the doctor (which are essential to treatment success). In general, Janumet is intended for use in adult patients only.
Janumet effectively enhances glycemic control in adults who suffer from type II diabetes. Containing both sitagliptin and metformin, it eliminates the inconvenience of taking two separate medications.